SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2025
0mins
Source: Globenewswire
Class Action Filed: A class action lawsuit has been initiated against Cerevel Therapeutics, Bain Capital, and Pfizer for alleged violations of federal securities laws related to misleading statements and insider trading during a secondary stock offering and subsequent merger discussions.
Investor Support Encouraged: Faruqi & Faruqi, LLP is urging investors who suffered losses from Cerevel's stock to contact them for legal options, with a deadline approaching for those wishing to become lead plaintiffs in the case.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
